DAFTAR PUSTAKA

1. Rikesdas. (2013). *Riset Kesehatan Dasar*. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI.
2. Rocco, M. V., & Berns, J. S. (2012). KDOQI clinical practice guideline for diabetes and CKD: 2012 update. American Journal of Kidney Diseases, 60(5), 850–886. https://doi.org/10.1053/j.ajkd.2012.07.005
3. Crawford, P. W., & Lerma, E. V. (2008). Treatment Options for End Stage Renal Disease, 35, 407–432. https://doi.org/10.1016/j.pop.2008.05.003
4. Fauziati, Ana (2014). Global challenge of early detection and management of Chronic Kidney Disease, Jurnal Kedokteran dan Kesehatan Indonesia, 1–2. https://doi.org/10.1371/journal.pone.0158765.2.
5. Indonesian, P., Registry, R., & Course, H. (2018). 10 th Report Of Indonesian Renal Registry 2017 10 th Report Of Indonesian Renal Registry 2017.
6. Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia (2017). SituasiPenyakit Ginjal Kronis, ISSN : 2442-7659
7. Al-Ramahi, R., Raddad, A. R., Rashed, A. O., Bsharat, A., Abu-Ghazaleh, D., Yasin, E., & Shehab, O. (2016). Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. BMC Nephrology, 17(1), 1–6. https://doi.org/10.1186/s12882-016-0317-4
8. Manley, H. J., Drayer, D. K., & Muther, R. S. (2003). Medication-related problem type and appearance rate in ambulatory hemodialysis patients, 7, 1–7.
9. Alshamrani, M., Almalki, A., Qureshi, M., Yusuf, O., & Ismail, S. (2018). Polypharmacy and Medication-Related Problems in Hemodialysis Patients: A Call for Deprescribing. Pharmacy, 6(3), 76. https://doi.org/10.3390/pharmacy6030076
10. Kaplan, B., Mason, N. A., Shimp, L. A., & Ascione, F. (1994). CHRONIC HEMODIALYSIS PATIENTS . PART I : CHARACTERIZATION AND DRUG-RELATED PROBLEMS, 28, 28–31.

11. Soetikno, V., Effendi, Imam., Nafrialdi. & Setiabudy, Rianto., 2009. A survey on the appropriateness of drug therapy in patients with renal dysfunction at the Internal Medicine Ward FMUI/Dr. Cipto Mangunkusumo Hospital. Medical Journal of Indonesia, 18 (Drug therapy in renal dysfunction), p. 108-113
12. Alshamrani M, Almalki A, Qureshi M, Yusuf O, Ismail S. Polypharmacy and Medication-Related Problems in Hemodialysis Patients: A Call for Deprescribing. Pharmacy [Internet]. 2018;6(3):76. Available from: http://www.mdpi.com/2226-4787/6/3/76
13. Via-sosa MA, Lopes N, March M. Effectiveness of a drug dosing service provided by community pharmacists in polymedicated elderly patients with renal impairment — a comparative study. BMC Fam Pract [Internet]. 2013;14(1):1. Available from: BMC Family Practice
14. Mckinnon A, Acpr BSP. Practice Spotlight : Pharmacist in a Chronic Kidney Disease Clinic. 2010;63(6):452–3.
15. Salgado TM, Moles R, Benrimoj SI, Fernandez-llimos F. Pharmacists ' interventions in the management of patients with chronic kidney disease : a systematic review. 2012;(June 2011):276–92
16. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. (2016) Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS ONE 11(7): e0158765. https://doi.org/10.1371/journal.pone.0158765
17. Morad Z, Frcp M, Lin H, Mbbs C, Intmed M, Tungsanga K. Funding Renal Replacement Therapy in Southeast Asia: Building Public-Private Partnerships in Singapore, Malaysia, Thailand, and Indonesia. Am J Kidney Dis [Internet]. 2015;65(5):799–805. Available from: http://dx.doi.org/10.1053/j.ajkd.2014.09.031
18. Allemann SS, Mil JWF Van, Botermann L, Berger K, Griese N, Hersberger KE. Pharmaceutical Care – the PCNE definition 2013. 2013;7703.
19. Cipolle, R. J., Strand, L. M., & Morley, P. C. (2004). Pharmaceutical care practice: The clinician's guide. 2nd Edition New York: McGraw-Hill, Medical Pub. Division.

20. Benjamin O, Lappin SL. End-Stage Renal Disease. [Updated 2018 Dec 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499861/)
21. National Lidney Foundation. Clinical practice guidelines for CKD. American Journal of Kidney Diseases. 2002. 54–65 p.
22. Sennang, N., Sulina, Badji, A., Hardjoeno. 2005. "Laju FiltrasiGlomerulus pada Orang Dewasa Berdasarkan Tes KlirensKreatinin Menggunakan Persamaan Cockroft-Gault danModification of Diet in Renal Disease". J.Med.Nus vol 24,No. 2. Hlm. 80-84
23. Carvalho ARM, Pinto CMA, Andriolo A, Guerra IC. Laboratory diagnosis of chronic kidney disease in adults : an overview of hospitals inserted in the Portuguese National Health System. 2017;(December):388–96.
24. Wilson LM. Pengobatan Gagal Ginjal Kronik. Dalam: Hartanto H, Susi N, Wulansari P, Mahanani DA, editor. Patofisiologi Konsep Klinis Proses - Proses Penyakit. 6 ed. Vol 2. Jakarta: EGC; 2006. hlm. 965-978.
25. Suwitra Ketut. Penyakit Ginjal Kronik. Dalam : Sehati S, Alwi I, Sudoyo AW, dkk, Editor. Buku Ajar Ilmu Penyakit Dalam Jilid II. Edisi IV. Jakarta Pusat : Interna Publishing : 2014 ; 2159-2165
26. Kementerian Kesehatan Republik Indonesia, Peraturan Menteri Kesehatan Republik Indonesia nomor 812 tahun 2010 tentang Penyelenggaraan Pelayanan Dialisis Pada Fasilitas Pelayanan Kesehatan
27. Cahyaningsih, Niken D. Hemodialisis (Cuci Darah) : Panduan Praktis Keperawatan Gagal Ginjal. Cetakan ke 3. Yogyakarta : Mitra Cendekia Press; 2013
28. Matzke GR, Aronoff GR, Jr AJA, Bennett WM, Decker BS, Eckardt K, et al. Drug dosing consideration in patients with acute and chronic kidney disease — a clinical update from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80(11):1122–37. Available from: http://dx.doi.org/10.1038/ki.2011.322
29. United States Renal Data System. 2015 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

2015. Available at: http:// www.usrds.org/adr.aspx. Last accessed: 9 February 2016.

30. Chesney RW, Han X, Patters AB. Taurine and the renal system. *J Biomed Sci*. 2010;17 Suppl 1(Suppl 1):S4. Published 2010 Aug 24. doi:10.1186/1423-0127-17-S1-S4

31. Yacoub R, Habib H, Lahdo A, Al Ali R, Varjabedian L, Atalla G, Kassis Akl N, Aldakheel S, Alahdab S, Albitar S. Association between smoking and chronic kidney disease: a case control study. BMC Public Health. 2010 Nov 25;10:731. doi: 10.1186/1471-2458-10-731. PMID: 21108832; PMCID: PMC3004836.

32. Verhelst D, Moulin P, Haufroid V, Wittebole X, Jadoul M, Hantson P. Acute Renal Injury Following Methanol Poisoning: Analysis of a Case Series. *International Journal of Toxicology*. 2004;23(4):267-273. doi:10.1080/10915810490506795

33. Khanna R. Clinical presentation & management of glomerular diseases: hematuria, nephritic & nephrotic syndrome. *Mo Med*. 2011;108(1):33-36.

34. Prakash S, O'Hare AM. Interaction of aging and chronic kidney disease. *Semin Nephrol*. 2009;29(5):497-503. doi:10.1016/j.semnephrol.2009.06.006

35. Goldberg I, Krause I. The Role Of Gender In Chronic Kidney Disease End-Stage Renal Disease. 2016;(April):58–64.

36. Fogo, A., Cohen, A.H., Colvin, R.B., Jennette, J.C., Alpers, C.E. Fundamental of Renal Pathology, Springer, Second Edition, 2014

37. Coates PT, Devuyst O, Wong G, Okusa M, Oliver J, York N, et al. KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020;98(4).

38. Trihono PP, Putri ND, Pulungan AB. Prognostic factors and survivals of children with steroid-resistant nephrotic syndrome Paediatrica Indonesiana. 2013;53(1):42–9.

39. Hemmelgarn BR, Manns BJ, Quan H, Ghali WA. Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis. 2003 Jul;42(1):125-32. doi: 10.1016/s0272-6386(03)00415-3. PMID: 12830464.

40. Lee W, Lee Y, Li L, Ng H, Kuo W, Lin P, et al. The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3 – 5 Chronic Kidney Disease. 2018;

41 Bucharles Sérgio Gardano Elias, Wallbach Krissia K.S., Moraes Thyago Proença de, Pecoits-Filho Roberto. Hypertension in patients on dialysis: diagnosis, mechanisms, and management. J. Bras. Nefrol. [Internet]. 2019 Sep [cited 2020 Oct 23] ; 41(3): 400-411. Epub Nov 08, 2018. https://doi.org/10.1590/2175-8239-jbn-2018-0155.

42. Utami, M., Rosa, E., & Khoiriyati, A. (2017). Gambaran Komorbid Pasien Hemodialisa. *STRADA Jurnal Ilmiah Kesehatan*, *6*(1), 18-23. Retrieved from https://sjik.org/index.php/sjik/article/view/134

43. Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. *Journal of the American Society of Nephrology : JASN*, *23*(10), 1631–1634. https://doi.org/10.1681/ASN.2011111078

44. Inrig JK. Antihypertensive agents in hemodialysis patients: a current perspective. Semin Dial. 2010 May-Jun;23(3):290-7. doi: 10.1111/j.1525-139X.2009.00697.x. Epub 2010 Mar 29. PMID: 20374548; PMCID: PMC3061334.

45. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2012;2(5).

46. Pugh, Dan et al. "Management of Hypertension in Chronic Kidney Disease." *Drugs* vol. 79,4 (2019): 365-379. doi:10.1007/s40265-019-1064-1

47. Ojha JP. Review article Management of dyslipidemia in CKD , dialysis and renal transplant recipient. Clin Queries Nephrol [Internet]. 2012;1(3):191–7. Available from: http://dx.doi.org/10.1016/j.cqn.2012.06.001

48. Capelli, I., Cianciolo, G., Gasperoni, L., Zappulo, F., Tondolo, F., Cappuccilli, M., & La Manna, G. (2019). Folic Acid and Vitamin B12 Administration in CKD, Why Not?. *Nutrients*, *11*(2), 383. https://doi.org/10.3390/nu11020383

49. Arnold, Ria et al. "Neurological complications in chronic kidney disease." *JRSM cardiovascular disease* vol. 5 2048004016677687. 3 Nov. 2016, https://doi.org/10.1177/2048004016677687

50. Dobre, M., Rahman, M., & Hostetter, T. H. (2015). Current status of bicarbonate in CKD. *Journal of the American Society of Nephrology : JASN*, *26*(3), 515–523. https://doi.org/10.1681/ASN.2014020205

51. National Kidney Foundation Kidney Disease Outcome Quality Initiative (NKF KDOQI). K/DOQI Clinical Practice Guidelines for Chronic Kid-ney Disease: Evaluation, Classification and Stratification.Am J Kidney Dis 39:S1-S266,2002 (suppl 1)

52. Chan S, Au K, Francis RS, Mudge DW, Johnson DW, Pillans PI. Phosphate binders in patients with chronic kidney disease. *Aust Prescr*. 2017;40(1):10-14. doi:10.18773/austprescr.2017.002

53. Davison S. N. (2015). Pain, analgesics, and safety in patients with CKD. *Clinical journal of the American Society of Nephrology : CJASN*, *10*(3), 350–352. https://doi.org/10.2215/CJN.00600115

54. Türck, D., Schwarz, A., Höffler, D. *et al.* Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. *E J Clin Pharmacol* **51,** 309–313 (1996). https://doi.org/10.1007/s002280050203

55. Heleniak Z, Cieplińska M, Szychliński T, et al. Nonsteroidal anti-inflammatory drug use in patients with chronic kidney disease. *J Nephrol*. 2017;30(6):781-786. doi:10.1007/s40620-016-0352-z

56. Strid H, Simre M, Bjo ES. Overuse of acid suppressant drugs in patients with chronic renal failure. 2003;570–5.

57. Zuvela J, Trimingham C, Le Leu R, Faull R, Clayton P, Jesudason S, Meade A. Gastrointestinal symptoms in patients receiving dialysis: A systematic review. Nephrology (Carlton). 2018 Aug;23(8):718-727. doi: 10.1111/nep.13243. PMID: 29468835.

58. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. *Clin J Am Soc Nephrol*. 2010;5(8):1388-1393. doi:10.2215/CJN.01580210

59. Asgari MR, Asghari F, Ghods AA, Ghorbani R, Hoshmand Motlagh N, Rahaei F. Incidence and severity of nausea and vomiting in a group of

maintenance hemodialysis patients. *J Renal Inj Prev*. 2016;6(1):49-55. Published 2016 Sep 3. doi:10.15171/jrip.2017.09

60. Eyler RF, Shvets K. Nephropharmacology for the Clinician Clinical Pharmacology of Antibiotics. 2019;14(7).
61. Jaber, BL. Bacterial infections in hemodialysis patients : Pathogenesis and prevention. Nephrology Forum. 2005;67:2508–19.
62. Nakhaee S, Nasiri A, Waghei Y, Morshedi J. Comparison of Avena sativa, vinegar, and hydroxyzine for uremic pruritus of hemodialysis patients: a crossover randomized clinical trial. Iran J Kidney Dis. 2015 Jul;9(4):316-22. PMID: 26174460.
63. Bousquet J, Maurice F, Rivory JP, Florence P, Chouzenoux R, Mion C. Allergy in long-term hemodialysis II . Allergic and atopic patterns of a population of patients undergoing long-term hemodialysis. 1987;
64. Mukaya JE, Jacobson MS, Esprit D, Ajayi T. Allergic reaction to polysulphone membrane dialyser masquerading as infection. *BMJ Case Rep*. 2015;2015:bcr2014208591. Published 2015 Feb 18. doi:10.1136/bcr-2014-208591
65. Kyung EJ, Kim HB, Hwang ES, Lee S, Choi BK, Kim JW, et al. Evaluation of Hepatoprotective Effect of Curcumin on Liver Cirrhosis Using a Combination of Biochemical Analysis and Magnetic Resonance-Based Electrical Conductivity Imaging. 2018;2018.
66. Cano, N. J., Aparicio, M., Brunori, G., Carrero, J. J., Cianciaruso, B., Fiaccadori, E., Lindholm, B., Teplan, V., Fouque, D., Guarnieri, G., & ESPEN (2009). ESPEN Guidelines on Parenteral Nutrition: adult renal failure. *Clinical nutrition (Edinburgh, Scotland)*, *28*(4), 401–414. https://doi.org/10.1016/j.clnu.2009.05.016
67. Navarro JF, et al. Amino acid losses during hemodialysis with polyacrylonitrile membranes: effect of intradialytic amino acid supplementation on plasma amino acid concentrations and nutritional variables innondiabetic patients. Am J Clin Nutr2000;71:765–73

68. Haller, C. “Hypoalbuminemia in renal failure: pathogenesis and therapeutic considerations.” *Kidney & blood pressure research* vol. 28,5-6 (2005): 307-10. doi:10.1159/000090185
69. Wyne, Ahraaz et al. “Opioid and benzodiazepine use in end-stage renal disease: a systematic review.” *Clinical journal of the American Society of Nephrology : CJASN* vol. 6,2 (2011): 326-33. doi:10.2215/CJN.04770610
70. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int. Issue V 2018;8(3).
71. Kim SM, Song IH. Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. *Korean J Intern Med*. 2018;33(4):670-678. doi:10.3904/kjim.2018.202
72. Perhimpunan Peneliti Hati Indonesia (PPHI) Perhimpunan Nefrologi Indonesia (PERNEFRI). Konsensus Nasional Penatalaksanaan Hepatitis C Pada Penyakit Ginjal Kronik di Indonesia., 2019
73. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(1):1-211. doi:10.1177/0333102417738202
74. Sav, M.Y., Sav, T., Senocak, E. and Sav, N.M. (2014), The pathophysiology of dialysis headache. Hemodial Int, 18: 725-729. doi:10.1111/hdi.12171
75. Sousa Melo, E., Carrilho Aguiar, F. and Sampaio Rocha-Filho, P.A. (2017), Dialysis Headache: A Narrative Review. Headache, 57: 161-164. doi:10.1111/head.12875
76. Sulowicz W, Radziszewski A. Pathogenesis and treatment of dialysis hypotension. 2006;
77. Palmer BF, Henrich WL. Recent Advances in the Prevention and Management of Intradialytic Hypotension. J Am Soc Nephrol [Internet]. 2008 Jan 1;19(1):8 LP – 11. Available from: http://jasn.asnjournals.org/content/19/1/8.
78. Fang JT, Huang CC. Midodrine hydrochloride in patients on hemodialysis with chronic hypotension. Ren Fail. 1996 Mar;18(2):253-60. doi: 10.3109/08860229609052795. PMID: 8723363.

79. Verduzco HA, Shirazian S. CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management. Kidney Int Rep. 2020 May 8;5(9):1387-1402. doi: 10.1016/j.ekir.2020.04.027. PMID: 32954065; PMCID: PMC7486142.
80. Ljutić D, Perković D, Rumboldt Z, Bagatin J, Hozo I, Pivac N. Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. Kidney Blood Press Res. 2002;25(1):61-4. doi: 10.1159/000049437. PMID: 11834879.
81. Kanda E. Causes of fever in dialysis patients and its treatment. OA Nephrology 2014 Mar 09;2(1):4
82. Beladi Mousavi SS, Zeraati A, Moradi S, Mousavi MB. The effect of gabapentin on muscle cramps during hemodialysis: A double-blind clinical trial. Saudi J Kidney Dis Transpl. 2015 Nov;26(6):1142-8. doi: 10.4103/1319-2442.168588. PMID: 26586051.
83. Moledina DG, Perry Wilson F. Pharmacologic Treatment of Common Symptoms in Dialysis Patients: A Narrative Review. Semin Dial. 2015 Jul-Aug;28(4):377-83. doi: 10.1111/sdi.12378. Epub 2015 Apr 25. PMID: 25913502.
84. Lynch PG, Abate M, Suh H, Wadhwa NK. Magnesium and Muscle Cramps in End Stage Renal Disease Patients on Chronic Hemodialysis. Abreo K, editor. Adv Nephrol [Internet]. 2014;2014:681969. Available from: https://doi.org/10.1155/2014/681969
85. Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V. Carnitine and hemodialysis. *Am J Kidney Dis*. 2003;41(3 Suppl 1):S116-S122. doi:10.1053/ajkd.2003.50099
86. El-Hennawy AS, Zaib S. A selected controlled trial of supplementary vitamin E for treatment of muscle cramps in hemodialysis patients. *Am J Ther*. 2010;17(5):455-459. doi:10.1097/MJT.0b013e3181b13c8f
87. Meydani M., Fielding R., Martin K.R. (1998) Vitamin E and its effect on skeletal muscle. In: Reznick A.Z., Packer L., Sen C.K., Holloszy J.O., Jackson M.J. (eds) Oxidative Stress in Skeletal Muscle. MCBU Molecular

and Cell Biology Updates. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8958-2_9

88. Galli F, Buoncristiani U, Conte C, Aisa C, Floridi A. Vitamin E in uremia and dialysis patients. Ann N Y Acad Sci. 2004 Dec;1031:348-51. doi: 10.1196/annals.1331.041. PMID: 15753167.

89. Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients. J Am Soc Nephrol. 2018 Jul;29(7):1970-1978. doi: 10.1681/ASN.2018010096. Epub 2018 Jun 5. PMID: 29871945; PMCID: PMC6050935.

90. Hyun K-S, Lee S-Y, Han S-S. The Effect of Topical Application of Lidocaine Cream before Arteriovenous(AV) Fistula Puncture on Pain and Anxiety Among Hemodialysis Patients. Korean J Adult Nurs. 2008 Jan 1;20.

91. Sridhar NR, Josyula S. Hypoalbuminemia in hemodialyzed end stage renal disease patients: risk factors and relationships--a 2 year single center study. *BMC Nephrol*. 2013;14:242. Published 2013 Nov 1. doi:10.1186/1471-2369-14-242

92. Haller C: Hypoalbuminemia in Renal Failure: Pathogenesis and Therapeutic Considerations. Kidney Blood Press Res 2005;28:307-310. doi: 10.1159/000090185

93. Perhimpunan Nefrologi Indonesia (PERNEFRI). Konsensus Nasional Manajemen Anemia Pada Penyakit Ginjal Kronik di Indonesia., 2011

94. Vargas-Santos AB, Neogi T. Management of Gout and Hyperuricemia in CKD. Am J Kidney Dis. 2017 Sep;70(3):422-439. doi: 10.1053/j.ajkd.2017.01.055. Epub 2017 Apr 26. PMID: 28456346; PMCID: PMC5572666.

95. Ramirez-Sandoval JC, Madero M. Treatment of Hyperuricemia in Chronic Kidney Disease. In: Contributions to Nephrology [Internet]. 2017. p. 135–46. Available from: https://www.karger.com/DOI/10.1159/000484288

96. Khan YH, Sarriff A, Adnan AS, Khan AH, Mallhi TH. Chronic Kidney Disease, Fluid Overload and Diuretics: A Complicated Triangle. PLoS One

[Internet]. 2016 Jul 21;11(7):e0159335. Available from: https://doi.org/10.1371/journal.pone.0159335

97. Erdem E. Proton pump inhibitors use in hemodialysis patients and serum magnesium levels. Int J Clin Exp Med. 2015 Nov 15;8(11):21689-93. PMID: 26885127; PMCID: PMC4723972.

98. Al-aly Z, Maddukuri G, Xie Y. Proton Pump Inhibitors and the Kidney : Implications of Current Evidence for Clinical Practice and When and How to Deprescribe. Am J Kidney Dis [Internet]. 75(4):497–507. Available from: https://doi.org/10.1053/j.ajkd.2019.07.012

99. Hans Strid, Magnus Simrén, Einar S. Björnsson, Overuse of acid suppressant drugs in patients with chronic renal failure, *Nephrology Dialysis Transplantation*, Volume 18, Issue 3, March 2003, Pages 570–575, https://doi.org/10.1093/ndt/18.3.570

100. Noiri E, Ozawa H, Fujita T, Nakao A. Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. Nephron. 2001 Sep;89(1):101-4. doi: 10.1159/000046050. PMID: 11528239

101. Min F, Tarlo SM, Bargman J, Poonai N, Richardson R, Oreopoulos D. Prevalence and causes of cough in chronic dialysis patients: a comparison between hemodialysis and peritoneal dialysis patients. Adv Perit Dial. 2000;16:129-33. PMID: 11045277

102. Bhandari M, Bhandari A, Bhandari A. Recent updates on codeine. Pharm Methods. 2011 Jan;2(1):3-8. doi: 10.4103/2229-4708.81082. PMID: 23781422; PMCID: PMC3658028

103. Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A. Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des. 2012;18(37):5994-6004. doi: 10.2174/138161212803582469. PMID: 22747535

104. Pham PC, Khaing K, Sievers TM, et al. 2017 update on pain management in patients with chronic kidney disease. *Clin Kidney J*. 2017;10(5):688-697. doi:10.1093/ckj/sfx080

105. Guay DR, Awni WM, Findlay JW, Halstenson CE, Abraham PA, Opsahl JA, Jones EC, Matzke GR. Pharmacokinetics and pharmacodynamics of codeine

in end-stage renal disease. Clin Pharmacol Ther. 1988 Jan;43(1):63-71. doi: 10.1038/clpt.1988.12. PMID: 3335120

106. Ohnishi K, Sakamoto N, Kobayashi K, Iwabuchi S, Nakamura-Uchiyama F, Ajisawa A, Yamauchi Y, Takeshita N, Yamamoto Y, Tsunoda T, Yoshimura Y, Tachikawa N, Uehira T. Subjective adverse reactions to metronidazole in patients with amebiasis. Parasitol Int. 2014 Oct;63(5):698-700. doi: 10.1016/j.parint.2014.05.006. Epub 2014 Jun 12. PMID: 24929036
107. Houghton, G. W., Dennis, M. J., & Gabriel, R. (1985). Pharmacokinetics of metronidazole in patients with varying degrees of renal failure. *British journal of clinical pharmacology*, *19*(2), 203–209. https://doi.org/10.1111/j.1365-2125.1985.tb02632.x
108. Lin, Julie, and Gary C Curhan. "Associations of sugar and artificially sweetened soda with albuminuria and kidney function decline in women." *Clinical journal of the American Society of Nephrology : CJASN* vol. 6,1 (2011): 160-6. doi:10.2215/CJN.03260410